Jasper Therapeutics, Inc. (JSPR): restructuring charge — Jasper Therapeutics cuts workforce ~50%, halts non-urticaria programs; CMO departs

Jasper Therapeutics, Inc.

Workforce reduction of ~50% and halting of all non-chronic urticaria programs.
Estimated $1.8M-$2.2M in severance cash expenditures through Q3 2025.
CMO Edwin Tucker departs effective Aug 1, 2025; receives 12 months base salary and COBRA.
Dr. Daniel Adelman appointed Acting Chief Medical Officer effective Aug 1, 2025.
Focus on briquilimab in CSU/CIndU; data from BEACON/SPOTLIGHT expected later this year.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Jasper Therapeutics, Inc. announced a restructuring with charges of approximately $1.8 million - $2.2 million affecting the Company (approximately 50%).

Type: restructuring
Charge: approximately $1.8 million - $2.2 million
Affected area: the Company
Headcount: approximately 50%

Exact text from the filing

in chronic urticaria and is halting other clinical and preclinical programs along with the reduction in workforce. The Company estimates that it will incur approximately $1.8 million - $2.2 million of cash expenditures in connection with the corporate reorganization, which relate to severance pay, and are expected to be incurred through the quarter ending

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-062194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.